ストックスクリーナーアプリを入手
1.13
2.73%
0.03
前日終値:
$1.10
開ける：
$1.11
24時間の取引高:
227.62K
Relative Volume:
0.61
時価総額：
$60.26M
収益：
-
当期純損益:
$-78.34M
株価収益率:
-0.7625
EPS:
-1.4819
ネットキャッシュフロー:
$-75.02M
1週間 パフォーマンス:
+3.67%
1か月 パフォーマンス:
-9.60%
6か月 パフォーマンス:
-8.13%
1年 パフォーマンス:
+2.73%
1日の値動き範囲:
$1.085
$1.15
1週間の範囲:
$1.05
$1.15
52週間の値動き範囲:
$0.9642
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
名前
Pmv Pharmaceuticals Inc
セクター
電話
(609) 642-6670
住所
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.13 | 60.26M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-05-13 | 開始されました | Craig Hallum | Buy |
| 2024-04-12 | 開始されました | Jefferies | Buy |
| 2023-12-27 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-03-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-09-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-08-19 | 開始されました | Oppenheimer | Perform |
| 2021-08-02 | 開始されました | Guggenheim | Buy |
| 2021-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Cowen | Outperform |
| 2020-10-20 | 開始されました | Evercore ISI | Outperform |
| 2020-10-20 | 開始されました | Goldman | Neutral |
すべてを表示
Pmv Pharmaceuticals Inc (PMVP) 最新ニュース
PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMV Pharmaceuticals Inc (PMVP) Valuation: PE, PB & Fair Value Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PMV Pharmaceuticals Inc (PMVP) Institutional Confidence - TradingKey
PMV Pharmaceuticals Inc (PMVP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMV Pharmaceuticals Inc (PMVP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Mitigates Stock DeclineEarnings Risk Report - newsline.com
PMV Pharmaceuticals Stock (US7301281085): Quiet session puts fundamentals and balance sheet in focus - AD HOC NEWS
PMV Pharmaceuticals (PMVP) loses 26% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
PMV Pharmaceuticals Slips Slightly as Shares Approach Critical SupportCounter Trend Trade - newsline.com
PMV Pharmaceuticals (PMVP) grants director 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals (PMVP) director receives 42,000 stock options at $1.1900 - Stock Titan
PMV Pharmaceuticals (PMVP) director gifts 84K stock options to trust - Stock Titan
PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19 - Stock Titan
Director at PMV Pharmaceuticals (PMVP) granted 42,000 options at $1.19 - Stock Titan
PMV Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
PMV Pharmaceuticals Shareholders Back Directors and Governance Matters - TipRanks
Shareholders back PMV Pharmaceuticals (NASDAQ: PMVP) board, pay plans - Stock Titan
PMVP: Directors elected, compensation and auditor ratified, with no stockholder questions raised - TradingView
PMV Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
PMV Pharmaceuticals Q1 2026 Earnings: EPS Beat Narrows Losses Amid Pre-Revenue Pipeline ProgressEarnings Season Outlook - newsline.com
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseNext Quarter Guidance - newsline.com
PMV Pharmaceuticals Advances Cancer Study Amid Adjusted Financial Targets - asatunews.co.id
PMV Pharmaceuticals Advances Cancer Drug Development Amid Financial Adjustments - sekbernews.id
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
PMVP Q1 2026 Earnings: Narrower Loss Slightly Beats Estimates as Development AdvancesRevenue Miss Report - The Legal Advocate
PMV Pharmaceuticals’ Phase 2 Clinical Trial Progresses; Reports $5 Million in First-Quarter Revenue - geneonline.com
PMV Pharmaceuticals (PMVP) Slips to $1.26 as Cautious Trading Puts Support to the TestCalendar Spread Trade - Newser
PMV Pharmaceuticals, Inc.Common Stock (Nasdaq:PMVP) Stock Quote - FinancialContent
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings Surprise: EPS $-0.34, Up SignificantProfit Cycle Analysis - The Legal Advocate
Number of shareholders of PMV Pharmaceuticals, Inc. – NASDAQ:PMVP - TradingView
Euclidean Capital reports 2.6M shares in PMVP (PMVP) - Stock Titan
PMV Pharmaceuticals (PMVP) Q1 2026 Earnings: Why the Beat MattersShared Trade Ideas - newser.com
PMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84 - MSN
PMVP Maintains Outperform Rating by Oppenheimer -- Price Target Lowered to $5.00 - GuruFocus
Oppenheimer Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
12 Health Care Stocks Moving In Wednesday's After-Market SessionAquestive Therapeutics (NASDAQ:AQST) - Benzinga
Oppenheimer Adjusts Price Target on PMV Pharmaceuticals to $5 From $6, Maintains Outperform Rating - marketscreener.com
TradingKey - TradingKey
PMVP Advances PYNNACLE Study and NDA Submission Timeline - GuruFocus
PMV Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
PMV Pharmaceuticals stock (US7301281085): Q1 2026 results and rezatapopt orphan drug nod - AD HOC NEWS
PMV Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
PMV Pharmaceuticals 1Q Loss/Shr 34c >PMVP - Moomoo
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
PMV Pharmaceuticals' Q1 net loss widens - TradingView
Pmv Pharmaceuticals Inc (PMVP) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):